Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.37 |
| ▸ | PLK4 | O00444 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | PRKCG | P05129 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | LYN | P07948 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29513107 | 1.00 | PTGER4 (0.41) | PTGER4KDM4EPOLBNNMTPLK4 | |
| SCHEMBL25095278 | 0.94 | PTGER4 (0.43) | PTGER4KDM4EPOLBNNMTPLK4 | |
| SCHEMBL27433147 | 0.94 | PTGER4 (0.39) | PTGER4KDM4EPOLBNNMTPLK4 | |
| SCHEMBL27433127 | 0.94 | KDM4E (0.40) | PTGER4KDM4EPOLBNNMTALDH1A1 | |
| SCHEMBL30966094 | 0.94 | KDM4E (0.40) | PTGER4KDM4EPOLBNNMTALDH1A1 | |
| SCHEMBL24771857 | 0.88 | PTGER4 (0.50) | PTGER4KDM4EGLAALDH1A1HTT | |
| SCHEMBL23552515 | 0.88 | PTGER4 (0.34) | PTGER4KDM4EPOLBNNMTPLK4 | |
| SCHEMBL27433442 | 0.80 | RPS6KB1 (0.36) | PTGER4KDM4EPOLBNNMTPLK4 | |
| SCHEMBL23529360 | 0.79 | POLB (0.44) | KDM4EPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL22904902 | 0.76 | NNMT (0.43) | KDM4EPOLBNNMTCHEK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638460-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024130341-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130341-A1 | BENZIMIDAZOLE DERIVATIVES FOR THE MODULATION OF STING | Aculeus Therapeutics Pty Ltd (AU) | 2024-06-27 | — | — | WO | disclosed |
| EP-3999185-B1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD (AU) | 2023-08-30 | — | — | EP | disclosed |
| US-20230062932-A1 | COMPOUNDS | CTXT PTY LTD. (AU) | 2023-03-02 | — | — | US | disclosed |
| WO-2022266711-A1 | SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS | Aculeus Therapeutics Pty Ltd (AU) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022266711-A1 | SUBSTITUTED AMIDOBENZIMIDAZOLE DIMERS AS STING MODULATORS | Aculeus Therapeutics Pty Ltd (AU) | 2022-12-29 | — | — | WO | disclosed |
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LTD. (AU) | 2022-12-08 | — | — | US | disclosed |
| EP-4077318-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021119753-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021119753-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021009365-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | CTXT PTY LIMITED (AU) | 2021-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389032-A1 | BENZOTHIOPHENE, THIENOPYRIDINE AND THIENOPYRIMIDINE DERIVATIVES FOR THE MODULATION OF STING | STING1, CGAS, MAVS | PTGER4 508/4885KDM4E 1256/4885POLB 927/4885 |
| US-20230062932-A1 | COMPOUNDS | STING1, IRF3, MAVS | PTGER4 1526/4885KDM4E 3952/4885POLB 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.